Welcome to Takeda’s resource hub for retail investors. Here you can sign up for email alerts, stay up to date on financial results and corporate milestones, and learn how Takeda is delivering on our commitment to patients, our people, and the planet.
Stay up to date on our covid-19 efforts, visit: www.takeda.com/covid-19-information-center
Guided by our values and our commitment to Patients, People and Planet, Takeda is delivering on its financial commitments, including the strategic allocation of capital to growth drivers, debt reduction, and shareholder returns.
We make disciplined and focused investments in value-creating business opportunities including R&D, new product launches, including in China, and plasma-derived therapies, and have committed to maintaining solid investment grade credit ratings. In respect of "Shareholder returns", Takeda has maintained its well-established dividend policy of 180 yen per share annually.
We leverage our own research Capabilities, while also acitively engaging with innovative ecosystems around the world to translate science into highly transformative or curative potential medicines for targeted populations with a high unmet need
As of March 2021. References: FY2020 Q4 Investor Presentation; Corporate Overview
1USD included for reference, calculated at JPY/USD of 110.6
2Non-IFRS measure. Further information on this and other Takeda Non-IFRS measures is posted on Takeda’s investor relations website
Visit our dedicated page for the 145th Ordinary General Meeting of Shareholders
Learn how we’re helping to solve key societal challenges and creating value for society by using our core strengths and capabilities
You may contact a licensed stockbroker or go through any registered broker-dealer to purchase shares of Takeda.
Takeda’s common shares are listed on the Tokyo Stock Exchange and trades using stock code “4502.” Our ADSs are traded on the New York Stock Exchange using the symbol “TAK”.
An American Depositary Receipt (ADR) is a certificate representing ownership of American Depositary Shares (ADSs) in a non-U.S. corporation. They include the right to vote at and attend AGMs, the receipt of dividends, and other common shareholder rights. One ADS represents 0.5 shares of Takeda’s common stock.
Takeda has maintained a well-established dividend policy of 180 yen per share annually.
Takeda’s dividend payments have historically been issued on a semi-annual basis in June and December.
Takeda’s fiscal year ends on March 31st. You can find our earnings materials and dates on our financial results webpage.
Takeda’s official reporting currency is the yen.
Takeda follows the International Financial Reporting Standards, or IFRS, for its financial reporting.
To send a comment or question to Takeda Pharmaceutical Company Limited, please visit: https://www.takeda.com/who-we-are/contact-us/
To subscribe to email alerts from Takeda, please use the form at the top of this page.
For feedback or inquiries, please visit https://www.takeda.com/who-we-are/contact-us/